

Reference number(s) 5892-D

This document applies to the following:

Product	Applies
Medicare Part B	V
Medicare Part B: Advanced Biosimilars First	V

Medicare Part B Step Therapy Antimetabolites

This document informs prescribers of preferred products and provides an exception process for non-preferred products through prior authorization.

These criteria were developed to align with the following: Medicare Part B and Medicare Part B Advanced Biosimilars First.

Plan Design Summary

This program applies to the antimetabolite products specified in this document. Coverage for non-preferred products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with the non-preferred product.

Step therapy is applied in addition to any applicable National Coverage Determination (NCD), Local Coverage Determination (LCD), and Medicare Part B utilization management (UM) programs implemented for the client.

Table. Antimetabolites

Medications considered preferred on your plan may still require a clinical prior authorization review.

	Product(s)
Preferred	pemetrexed (generic)
Non-preferred	Alimta (pemetrexed)Pemfexy (pemetrexed)

MedB ST Antimetabolites MED B-MED B ABF 5892-D P2026.docx

© 2026 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Step Therapy Criteria

Coverage for a non-preferred product is provided when any of the following criteria is met:

- Member has received treatment with the non-preferred product in the past 365 days.
- Member has had a documented intolerable adverse event to the preferred product, and the
 adverse event was not an expected adverse event attributed to the active ingredient as
 described in the prescribing information.

References

- 1. Alimta [package insert]. Indianapolis, IN: Lilly USA, LLC; May 2023.
- 2. Pemetrexed [package insert]. Lake Forest, IL: Hospira, Inc.; February 2023.
- 3. Pemfexy [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; December 2022.